此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

卡博替尼用于既往接受过治疗的神经内分泌肿瘤患者的研究 (CaboLife)

2026年9月29日 更新者:Ipsen

CaboLife:一项关于卡博替尼在真实世界环境中治疗既往接受过治疗的神经内分泌肿瘤患者的有效性和安全性的前瞻性非干预性研究

This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).

These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.

The study will take place in regular hospitals and clinics in Germany and Austria.

It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.

This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.

研究概览

地位

招聘中

研究类型

观察性的

注册 (估计的)

150

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Graz、奥地利
        • 招聘中
        • Medizinische Universitaet Graz
      • Linz、奥地利
        • 尚未招聘
        • Kepler Universitaetsklinikum GmbH Linz
      • Vienna、奥地利
        • 招聘中
        • Medizinische Universität Wien
      • Aschaffenburg、德国
        • 招聘中
        • MVZ am Klinikum Aschaffenburg
      • Berlin、德国
        • 招聘中
        • Evangelische Lungenklinik Berlin
      • Berlin、德国
        • 招聘中
        • DRK Kliniken Berlin
      • Berlin、德国
        • 招聘中
        • Charité - Universitaetsmedizin Berlin
      • Bonn、德国
        • 尚未招聘
        • Johanniter-Kliniken Bonn
      • Bremen、德国
        • 招聘中
        • Krankenhaus St. Joseph-Stift Bremen GmbH
      • Chemnitz、德国
        • 尚未招聘
        • Klinikum Chemnitz
      • Cologne、德国
        • 招聘中
        • pioh Studien und Mangement GbR
      • Cologne、德国
        • 招聘中
        • MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
      • Dresden、德国
        • 招聘中
        • Gemeinschaftspraxis Haematologie - Onkologie
      • Dresden、德国
        • 招聘中
        • Technische Univiersitaet (TU) Dresden
      • Erlangen、德国
        • 招聘中
        • Universitaetsklinikum Erlangen
      • Essen、德国
        • 招聘中
        • Universitaetsklinikum Essen
      • Frankfurt、德国
        • 尚未招聘
        • Krankenhaus Nordwest
      • Frankfurt am Main、德国
        • 尚未招聘
        • Uniklinikum Frankfurt
      • Freiburg im Breisgau、德国
        • 招聘中
        • Universitaetsklinikum Freiburg
      • Giesen、德国
        • 尚未招聘
        • Universitaetsklinikum Giessen-Marburg
      • Goettigen、德国
        • 招聘中
        • Universitaetsmedizin Goettingen
      • Hamburg、德国
        • 招聘中
        • Universitaetsklinikum Hamburg-Eppendorf
      • Hamburg、德国
        • 尚未招聘
        • Asklepios Kliniken Hamburg
      • Heidelberg、德国
        • 尚未招聘
        • Universitaetsklinikum Heidelberg
      • Kiel、德国
        • 尚未招聘
        • UKSH Kiel
      • Leer、德国
        • 尚未招聘
        • Studienzentrum UnterEms
      • Leipzig、德国
        • 尚未招聘
        • MVZ Leipzig Mitte, MVZ Delitzsch
      • Leipzig、德国
        • 尚未招聘
        • Universiteatsmedizin Leipzig
      • Ludwigsburg、德国
        • 招聘中
        • RKH Kliniken Ludwigsburg-Bietigheim gGmbH
      • Lübeck、德国
        • 尚未招聘
        • UKSH Luebeck
      • Mainz、德国
        • 尚未招聘
        • Universitaetsmedizin Mainz
      • Marburg、德国
        • 招聘中
        • Philipps-Universitaet Marburg
      • Minden、德国
        • 招聘中
        • Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
      • Mülheim、德国
        • 招聘中
        • MVZ Muelheim an der Ruhr GmbH
      • München、德国
        • 尚未招聘
        • TUM Klinikum Muenchen
      • Münster、德国
        • 尚未招聘
        • Universitaetsklinikum Muenster
      • Osnabrück、德国
        • 尚未招聘
        • MVZ Onkologie Klinikum Osnabrueck GmbH
      • Saarbrücken、德国
        • 尚未招聘
        • Universitaestklinikum Saarbruecken
      • Tübingen、德国
        • 招聘中
        • Universitätsklinikum Tuebingen
      • Westerstede、德国
        • 招聘中
        • Medizinische Studiengesellschaft Nord-West
      • Würzburg、德国
        • 招聘中
        • Universitaetsklinikum Wuerzburg

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.

描述

Inclusion Criteria:

Participants can join the study if they meet all of the following conditions:

  • Are 18 years or older and able to give informed consent.
  • Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
  • Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
  • Have already received at least one prior systemic therapy, other than somatostatin analogues.
  • Have signed a written informed consent form.

Exclusion Criteria:

Participants cannot join the study if:

  • They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
  • They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Disease Control Rate (DCR)
大体时间:At 6 Months

Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care.

At 6 Months

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:Up to 18 Months

Proportion of participants who achieve complete or partial response based on radiographic assessments.

Up to 18 Months
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
大体时间:Baseline and Every 3 Months up to 18 Months

A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties).

Baseline and Every 3 Months up to 18 Months
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
大体时间:Baseline and Every 3 Months up to 18 Months

A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning).

Baseline and Every 3 Months up to 18 Months
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
大体时间:Up to 18 Months

An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention.

Up to 18 Months
Percentage of participants with any dose modification due to AEs.
大体时间:Up to 18 months

Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period.

Up to 18 months
Duration of treatment (DoT)
大体时间:Up to 18 Months

Time from first dose to last dose of cabozantinib.

Up to 18 Months
Percentage of participants switching to a new line of therapy
大体时间:Up to 18 Months

Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure.

Up to 18 Months
Disease control rate after switch to next line of therapy
大体时间:3 Months After Therapy Switch

Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care.

3 Months After Therapy Switch
Chromogranin A Levels
大体时间:Baseline and Every 3 Months up to 18 Months

Chromogranin A blood levels measured during routine care.

Baseline and Every 3 Months up to 18 Months
Neuron-Specific Enolase blood levels.
大体时间:Baseline and Every 3 Months up to 18 Months

Neuron-Specific Enolase blood levels measured during routine care.

Baseline and Every 3 Months up to 18 Months
Time to next treatment
大体时间:Up to 18 Months

Time from first dose of cabozantinib to initiation of subsequent therapy.

Up to 18 Months
Progression-Free Survival (PFS)
大体时间:Up to 18 Months

Time from first dose of cabozantinib to disease progression or death from any cause.

Up to 18 Months
Progression-Free Survival Rate at 12 and 18 Months
大体时间:At 12 and 18 Months

Number of participants without disease progression or death.

At 12 and 18 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Ipsen Medical Director、Ipsen

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月17日

初级完成 (估计的)

2027年10月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2025年12月18日

首先提交符合 QC 标准的

2025年12月18日

首次发布 (实际的)

2026年1月2日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD 共享时间框架

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).

IPD 共享访问标准

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅